Roberts E, Frankel S. Gamma-aminobutyric acid in brain: its formation from glutamic acid. J Biol Chem (1950) 187(1):55-63
Olsen RW, Sieghart W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev (2008) 60(3):243-60. doi:10.1124/pr.108.00505
Buddhala C, Hsu CC, Wu JY. A novel mechanism for GABA synthesis and packaging into synaptic vesicles. Neurochem Int (2009) 55(1-3):9-12. doi:10.1016/j.neuint.2009.01.020
Mohler H. GABA(A) receptor diversity and pharmacology. Cell Tissue Res (2006) 326(2):505-16. doi:10.1007/s00441-006-0284-3
Pinard A, Seddik R, Bettler B. GABAB receptors: physiological functions and mechanisms of diversity. Adv Pharmacol (2010) 58:231-55. doi:10.1016/S1054-3589(10)58010-4
Gladkevich A, Korf J, Hakobyan VP, Melkonyan KV. The peripheral GABAergic system as a target in endocrine disorders. Auton Neurosci (2006) 124(1-2):1-8. doi:10.1016/j.autneu.2005.11.002
Auteri M, Zizzo MG, Serio R. GABA and GABA receptors in the gastrointestinal tract: from motility to inflammation. Pharmacol Res (2015) 93:11-21. doi:10.1016/j.phrs.2014.12.001
Bhat R, Axtell R, Mitra A, Miranda M, Lock C, Tsien RW, et al. Inhibitory role for GABA in autoimmune inflammation. Proc Natl Acad Sci U S A (2010) 107(6):2580-5. doi:10.1073/pnas.0915139107
Tian J, Lu Y, Zhang H, Chau CH, Dang HN, Kaufman DL. Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. J Immunol (2004) 173(8):5298-304. doi:10.4049/jimmunol.173.8.5298
Kelley JM, Hughes LB, Bridges SL Jr. Does gamma-aminobutyric acid (GABA) influence the development of chronic inflammation in rheumatoid arthritis? J Neuroinflammation (2008) 5:1. doi:10.1186/1742-2094-5-1
Tian J, Yong J, Dang H, Kaufman DL. Oral GABA treatment downregulates inflammatory responses in a mouse model of rheumatoid arthritis. Autoimmunity (2011) 44(6):465-70. doi:10.3109/08916934.2011.571223
Nigam R, El-Nour H, Amatya B, Nordlind K. GABA and GABA(A) receptor expression on immune cells in psoriasis: a pathophysiological role. Arch Dermatol Res (2010) 302(7):507-15. doi:10.1007/s00403-010-1052-5
Prud'homme GJ, Glinka Y, Hasilo C, Paraskevas S, Li X, Wang Q. GABA protects human islet cells against the deleterious effects of immunosuppressive drugs and exerts immunoinhibitory effects alone. Transplantation (2013) 96(7):616-23. doi:10.1097/TP.0b013e31829c24be
Prud'homme GJ, Glinka Y, Udovyk O, Hasilo C, Paraskevas S, Wang Q. GABA protects pancreatic beta cells against apoptosis by increasing SIRT1 expression and activity. Biochem Biophys Res Commun (2014) 452(3):649-54. doi:10.1016/j.bbrc.2014.08.135
Soltani N, Qiu H, Aleksic M, Glinka Y, Zhao F, Liu R, et al. GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. Proc Natl Acad Sci U S A (2011) 108(28):11692-7. doi:10.1073/pnas.1102715108
Tian J, Dang HN, Yong J, Chui WS, Dizon MP, Yaw CK, et al. Oral treatment with gamma-aminobutyric acid improves glucose tolerance and insulin sensitivity by inhibiting inflammation in high fat diet-fed mice. PLoS One (2011) 6(9):e25338. doi:10.1371/journal.pone.0025338
Alenghat T, Osborne LC, Saenz SA, Kobuley D, Ziegler CG, Mullican SE, et al. Histone deacetylase 3 coordinates commensal-bacteria-dependent intestinal homeostasis. Nature (2013) 504(7478):153-7. doi:10.1038/nature12687
Sun T, Gao GZ, Li RF, Li X, Li DW, Wu SS, et al. Bone marrow-derived mesenchymal stem cell transplantation ameliorates oxidative stress and restores intestinal mucosal permeability in chemically induced colitis in mice. Am J Transl Res (2015) 7(5):891-901
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 353(23):2462-76. doi:10.1056/NEJMoa050516
Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2014) 146(1):96-109.e1. doi:10.1053/j.gastro.2013.06.010
Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2012) 142(2):257-65.e1-3. doi:10.1053/j.gastro.2011.10.032
Ranganathan P, Jayakumar C, Li DY, Ramesh G. UNC5B receptor deletion exacerbates DSS-induced colitis in mice by increasing epithelial cell apoptosis. J Cell Mol Med (2014) 18(7):1290-9. doi:10.1111/jcmm.12280
Li B, Alli R, Vogel P, Geiger TL. IL-10 modulates DSS-induced colitis through a macrophage-ROS-NO axis. Mucosal Immunol (2014) 7(4):869-78. doi:10.1038/mi.2013.103
Liu S, Li Y, Deng B, Xu Z. Recombinant Lactococcus lactis expressing porcine insulin-like growth factor I ameliorates DSS-induced colitis in mice. BMC Biotechnol (2016) 16:25. doi:10.1186/s12896-016-0255-z
Chassaing B, Aitken JD, Malleshappa M, Vijay-Kumar M. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol (2014) 104:Unit 15.25. doi:10.1002/0471142735.im1525s104
Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology (2002) 122(1):44-54. doi:10.1053/gast.2002.30294
Lomasney KW, Cryan JF, Hyland NP. Converging effects of a Bifidobacterium and Lactobacillus probiotic strain on mouse intestinal physiology. Am J Physiol Gastrointest Liver Physiol (2014) 307(2):G241-7. doi:10.1152/ajpgi.00401.2013
Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol (1993) 123(6 Pt 2):1777-88. doi:10.1083/jcb.123.6.1777
Koval M. Claudins-key pieces in the tight junction puzzle. Cell Commun Adhes (2006) 13(3):127-38. doi:10.1080/15419060600726209
Van Itallie CM, Anderson JM. Claudins and epithelial paracellular transport. Annu Rev Physiol (2006) 68:403-29. doi:10.1146/annurev.physiol.68.040104.131404
Reyes-Garcia MG, Hernandez-Hernandez F, Hernandez-Tellez B, Garcia-Tamayo F. GABA (A) receptor subunits RNA expression in mice peritoneal macrophages modulate their IL-6/IL-12 production. J Neuroimmunol (2007) 188(1-2):64-8. doi:10.1016/j.jneuroim.2007.05.013
Maldonado-Contreras AL, McCormick BA. Intestinal epithelial cells and their role in innate mucosal immunity. Cell Tissue Res (2011) 343(1):5-12. doi:10.1007/s00441-010-1082-5
Iwashita J, Sato Y, Sugaya H, Takahashi N, Sasaki H, Abe T. mRNA of MUC2 is stimulated by IL-4, IL-13 or TNF-alpha through a mitogen-activated protein kinase pathway in human colon cancer cells. Immunol Cell Biol (2003) 81(4):275-82. doi:10.1046/j.1440-1711.2003.t01-1-01163.x
McElroy SJ, Prince LS, Weitkamp JH, Reese J, Slaughter JC, Polk DB. Tumor necrosis factor receptor 1-dependent depletion of mucus in immature small intestine: a potential role in neonatal necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol (2011) 301(4):G656-66. doi:10.1152/ajpgi.00550.2010
Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol (2013) 108(8):1268-76. doi:10.1038/ajg.2013.138
Karin M, Clevers H. Reparative inflammation takes charge of tissue regeneration. Nature (2016) 529(7586):307-15. doi:10.1038/nature17039
Bel S, Elkis Y, Lerer-Goldstein T, Nyska A, Shpungin S, Nir U. Loss of TMF/ARA160 protein renders colonic mucus refractory to bacterial colonization and diminishes intestinal susceptibility to acute colitis. J Biol Chem (2012) 287(30):25631-9. doi:10.1074/jbc.M112.364786
Zoetendal EG, Rajilic-Stojanovic M, de Vos WM. High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut (2008) 57(11):1605-15. doi:10.1136/gut.2007.133603
Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang AP, et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med (2011) 3(96):96ra76. doi:10.1126/scitranslmed.3002648
Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia (2000) 41(Suppl 1):S3-9. doi:10.1111/j.1528-1157.2000.tb02163.x
Guerrini R, Parmeggiani L. Topiramate and its clinical applications in epilepsy. Expert Opin Pharmacother (2006) 7(6):811-23. doi:10.1517/14656566.7.6.811
Aggarwal S, Ahuja V, Paul J. Attenuated GABAergic signaling in intestinal epithelium contributes to pathogenesis of ulcerative colitis. Dig Dis Sci (2017) 62(10):2768-79. doi:10.1007/s10620-017-4662-3
Inoue K, Shirai T, Ochiai H, Kasao M, Hayakawa K, Kimura M, et al. Blood-pressure-lowering effect of a novel fermented milk containing gamma-aminobutyric acid (GABA) in mild hypertensives. Eur J Clin Nutr (2003) 57(3):490-5. doi:10.1038/sj.ejcn.1601555
Abdou AM, Higashiguchi S, Horie K, Kim M, Hatta H, Yokogoshi H. Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans. Biofactors (2006) 26(3):201-8. doi:10.1002/biof.5520260305
Komatsuzaki N, Nakamura T, Kimura T, Shima J. Characterization of glutamate decarboxylase from a high gamma-aminobutyric acid (GABA)-producer, Lactobacillus paracasei. Biosci Biotechnol Biochem (2008) 72(2):278-85. doi:10.1271/bbb.70163
Korpi ER, Sinkkonen ST. GABA(A) receptor subtypes as targets for neuropsychiatric drug development. Pharmacol Ther (2006) 109(1-2):12-32. doi:10.1016/j.pharmthera.2005.05.009
